Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) formats, becoming the country’s only company to offer the drug in all three biotechnology dosage forms: vials, pre-filled syringes, and pre-filled pens.
Semaglutide, a GLP-1 receptor agonist, is widely used for the management of Type 2 diabetes and is increasingly recognized for its role in weight and metabolic management.
The principal activity of the company is to manufacture and market pharmaceutical products.